Simultaneous Estimation of Tramadol HCl, Paracetamol and Domperidone in Pharmaceutical Formulation by RP-HPLC Method

Keyur B. Ahir, Emanuel M. Patelia* and Falgun A. Mehta
Department of Pharmaceutical Chemistry and Analysis, Indukaka Ipacowala College of Pharmacy, New Vallabh Vidyanagar–388121, Gujarat, India

Abstract

A simple, precise, rapid, selective, and economic reversed phase high-performance liquid chromatography (RP-HPLC) method has been established for simultaneous analysis of A Phenomenex C18 (250×4.6 mm i.d.) chromatographic column equilibrated with mobile phase 0.02 M Potassium dihydrogen orthophosphate/acetonitrile (55/45, v/v) adjusted to pH 6.5 with Triethyamine (1% v/v) was used. Mobile phase flow rate was maintained at 1 ml/min and effluents were monitored at 278 nm. The sample was injected using a 20 µl fixed loop, and the total run time was 10 min. Experimental conditions such as pH of mobile phase, column saturation time, selection of wavelength, etc. were critically studied and the optimum conditions were selected. The retention time for PCM, DMP and TMD were 3.76 min, 5.18 min and 4.28 min, respectively. The calibration curve for DMP, PCM and TMD was found to be linear in the range of 0.2–1 µg/ml, 6.5–32.5 µg/ml and 0.75–3.75 µg/ml with a correlation coefficient of 0.9998, 0.9976 and 0.9974. The detection limits for PCM, DMP and TMD were 20 ng/ml, 1.06 ng/ml and 2 ng/ml, respectively, while quantitation limits were 60 ng/ml, 3.23 ng/ml and 6 ng/ml, respectively. This HPLC procedure is economic, sensitive, and less time consuming than other chromatographic procedures. It is a user-friendly and importance tool for analysis of combined tablet dosage forms.

Keywords: HPLC; Paracetamol; Domperidone; Tramadol HCl tablet; Validation

Introduction

PCM (PCM; N-[4-hydroxyphenyl] ethanamide; Figure 1) is a widely used analgesic and antipyretic for the relief of fever, headaches, and other minor aches and pains, and is a major ingredient in numerous cold and flu remedies. In combination with nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics, paracetamol is used also in the management of severe pain (such as postoperative pain) [1]. Tramadol HCL (TMD; (+/-) cis-2-[(Dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride (Figure 1) is a centrally acting analgesic, having agonist actions at the μ-opioid receptor and affects reuptake at the noradrenergic and serotonergic systems. TMD is a compound with mild and delayed μ-agonist activity [2]. Domperidone (DMP; 5-chloro-1-[1-[3-(2-oxo-2, 3-dihydro-1H-benzimidazol-1-yl) propyl]-piperidin-4-yl]-1, 3-dihydro-2H-benzimidazol-2-one; Figure 1) used as antiemetic drug.

PCM is official in Indian Pharmacopoeia. This pharmacopeia suggests titrimetric and UV spectrophotometric assay method for PCM in bulk and tablet formulations. DMP is official in Indian Pharmacopoeia where assay is described by titrimetric method. Tramadol is official in Indian Pharmacopoeia. This pharmacopeia suggests titrimetric (potentiometric) assay method for tramadol in bulk. Literature survey revealed that various analytical methods like spectrophotometric [3-6], HPLC [7-14], GC [15] and HPTLC [16-19] have been reported for the determination of TMD, PCM and either individually or combination with some other drugs, but no HPTLC method was reported for simultaneous estimation of TMD and PCM and domperidol in combined dosage forms. Many methods [20-27] have been described in the literature for the determination of domperidol and paracetamol, individually. The analytical methods like HPLC [10] and HPTLC [28] for determination of domperidol and PCM in combined dosage form has been reported. The RP HPLC [29] method has been reported for estimation of TMD, PCM and Domperidol in tablet formulation. The review of literature prompted us to develop an accurate, selective and precise simultaneous method for the estimation of TMD, PCM and DMP in combined dosage forms.

Experimental

Chemicals and materials

TMD, PCM and DMP were procured from Cadila pharmaceuticals, Ahmedabad, Ethyl Acetate, Toluen, Ammonia and n-Butanol were used as solvents to prepare the mobile phase. All the reagents used were of Analytical reagent grade (CHEMDYES CORPORATION, Ahmedabad, India) and used without further purification. Tablet formulation A (Tramazac-PD, Zydus Cadila Healthcare Ltd., Ahmedabad, India) and Tablet formulation B (RAMCET-D sundyota numandis pharma, Ahmedabad, India) containing labeled amount of 325 mg PCM, 37.5 mg TMD, and 10 mg DMP were procured from local market.

*Corresponding author: Emanuel M Patelia, Department of Pharmaceutical Chemistry and Analysis, Indukaka Ipacowala College of Pharmacy, New Vallabh Vidyanagar–388121, Gujarat, India, E-mail: ricky.emanual@gmail.com

Received October 25, 2012; Accepted November 20, 2012; Published November 25, 2012

Citation: Ahir KB, Patelia EM, Mehta FA (2012) Simultaneous Estimation of Tramadol HCl, Paracetamol and Domperidone in Pharmaceutical Formulation by RP-HPLC Method. J Chromat Separation Techniq 3:152. doi: 10.4172/2157-7064.1000152

Copyright: © 2012 Ahir KB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Chromatographic conditions
A Phenomenex C18 (250×4.6 mm i.d) chromatographic column equilibrated with mobile phase 0.02 M Potassium dihydrogen orthophosphate/acetonitrile (55/45, v/v) adjusted to pH 6.5 with Trichydrochloric acid (1% v/v) was used. Mobile phase flow rate was maintained at 1 ml/min and effluents were monitored at 278 nm. The sample was injected using a 20 µL fixed loop, and the total run time was 10 min.

Sample preparation
To determine the content of PCM, DMP and TMD in combined dose tablet formulation twenty tablets of each brand were weighed. Average weight was calculated, the tablets were crushed and powder equivalent to about 325 mg PCM, 10 mg DMP and 37.5 TMD was transferred to 100.0 ml volumetric flask, 20.0 ml of methanol was added and content of the flask were ultrasonicated for 30 minutes, volume was made up to the mark with methanol. The solution was mixed and filtered through Whatman filter paper No. 41. From the filtrate, 1.0 ml was diluted to 100 ml with methanol. Appropriate volume of the aliquot was transferred to a 10 ml volumetric flask and the volume was made up to the mark with the mobile phase to obtain a solution containing DMP (0.6 µg/ml), PCM (19.5 µg/ml) and TMD (2.25 µg/ml) were applied to HPLC and analyzed for PCM, DMP and TMD content using the proposed method as described earlier. The possibility of interference from other components of the tablet formulation in the analysis was studied. From the developed chromatogram R values were determined.

Preparation of standard solution: PCM (325 mg), DMP (10 mg) and TMD (37.5 mg) were accurately weighed and transferred to 100 ml volumetric flask and dissolved in few ml of methanol and sonicate it for 15 minutes. Volumes were made up to the mark with methanol to yield a solution containing 100 µg/ml of DMP, 3250 µg/ml of PCM and 375 µg/ml of TMD.

Method validation
The developed method was validated for linearity and range, specificity, accuracy, precision, Limit of detection, Limit of quantitation, robustness and solution stability as per ICH guidelines.

Linearity and range: Linearity of the method was evaluated by constructing calibration curves at five concentration levels over a range of 0.2–1 µg/ml of DMP, 6.5–32.5 µg/ml of PCM and 0.75–3.75 µg/ml of TMD respectively. The calibration curves were developed by plotting peak area versus concentration (n=6).

Specificity: The specificity of the method was ascertained by analyzing PCM, DMP and TMD in presence of excipients like talc, polyethylene glycol, lactose and micro-crystalline cellulose were used for tablet formulations. The bands of PCM, DMP and TMD were confirmed by comparing R values and respective spectra of sample with those of standards. The peak purity of PCM, DMP and TMD was assured by comparing the chromatogram.

Accuracy (% Recovery): The accuracy of the method was determined by calculating recoveries of PCM, DMP and TMD by method of standard additions. Known amount of DMP (80%, 100%, 120%), PCM(80%, 100%, 120%) and TMD (80%, 100%, 120%) were added to a pre quantified sample solution, and the amount of PCM, DMP and TMD were estimated by measuring the peak areas and by fitting these values to the straight-line equation of calibration curve.

Method precision (Repeatability): The instrumental precision studies were carried out by estimating response of 3 different concentrations of DMP (0.2, 0.6, 1 µg/ml) PCM (6.5, 19.5, 32.5 µg/ml) and TMD (0.75, 2.25, 3.75 µg/ml) six times and results are reported in terms of relative standard deviation.

Intermediate precision (Reproducibility): The intra-day and inter-day precision studies were carried out by estimating the corresponding responses 3 times on the same day and on 3 different days for three different concentrations of DMP (0.2, 0.6, 1 µg/ml), PCM (6.5, 19.5, 32.5 µg/ml) and TMD (0.75, 2.25, 3.75 µg/ml), and the results are reported in terms of relative standard deviation.

Limits of Detection (LOD) and Limits of quantitation (LOQ): The limit of detection (LOD) is defined as the lowest concentration of an analyte that can reliably be differentiated from background levels. Limit of quantification (LOQ) of an individual analytical procedure is the lowest amount of analyte that can be quantitatively determined with suitable precision and accuracy. LOD and LOQ were calculated using following equation as per ICH guidelines. LOD=3.3×σ/S; LOQ=10×σ/S; Where σ is the standard deviation of y-intercepts of regression lines and S is the slope of the calibration curve.

Robustness: Robustness of the method was studied by changing the flow rate of the mobile phase from 1 ml/min to 0.9 ml/min and 1.1 ml/min. Using 1.1 ml/min flow rate, retention time for PCM, DMP and TMD were observed to be 2.96 min, 4.18 min and 3.68 min respectively and with 0.9 flow rate, retention time for PCM, DMP and TMD were found to be 3.83, 6.12 and 5.46 min respectively without affecting resolution of the drug. When a mobile phase composition was changed to 0.02 M KH2PO4/acetonicitrile (65/35 v/v; pH 6.5) by increasing percentage of buffer the retention time for PCM, DMP and TMD were observed to be 4.84 min, 6.18 min and 5.28 min respectively. When a mobile phase composition was changed to 0.02 M KH2PO4/acetonicitrile (35/65 v/v; pH 6.5) by increasing percentage of acetonicitrile the retention time for PCM, DMP and TMD were observed to be 2.86 min, 4.38 min and 3.18 min respectively The assay result of both the drug was found to be more than 98%.

Solution stability: The solutions at analytical concentration DMP (1 µg/ml), PCM (32.5 µg/ml) and TMD (3.75 µg/ml) were prepared and stored at room temperature for 24 h and analyzed at interval of 0, 6, 12 and 24 h for the presence of any band other than that of PCM, DMP and TMD and the results were simultaneously compared with the freshly prepared PCM, DMP and TMD standard solution of the same concentration in the form of change in %RSD of the response obtained.

Application of validated method to pharmaceutical formulation
To determine the content of PCM, DMP and TMD in combined dose tablet formulation twenty tablets of each brand were weighed. Average weight was calculated, the tablets were crushed and powder equivalent to about 325 mg PCM, 10 mg DMP and 37.5 TMD was transferred to 100.0 ml volumetric flask, 20.0 ml of methanol was added and content of the flask were ultrasonicated for 30 minutes, volume was made up to the mark with methanol. The solution was mixed and filtered through Whatman filter paper No. 41. Appropriate volume of the aliquot was transferred to a 10 ml volumetric flask and the volume was made up to the mark with the mobile phase to obtain a solution containing 0.6 µg/ml of DMP, 19.5 µg/ml of PCM and 2.25 µg/ml of TMD. The solution was sonicated for 10 min. It was injected as per the above chromatographic conditions and peak areas were recorded. Thus the validated method was used for analysis of PCM, TMD and DMP in their combined tablets dosage form (Brand A and B).
Results and Discussion

Method development and optimization of chromatographic conditions

The mobile phase 0.02 M KH$_2$PO$_4$/acetonitrile (55/45 v/v) total pH adjusted to 6.5 using triethylamine was found to be satisfactory and gave three symmetric and well-resolved peaks for PCM, DMP and TMD. The retention time for PCM, DMP and TMD were 3.76 min, 5.18 min and 4.28 min, respectively. The resolution between PCM, DMP and TMD was found to be 2.4, which indicates good separation of three of the compounds [17]. The asymmetric factors for PCM, DMP and TMD were 1.32, 1.29 and 1.14, respectively. The mobile phase flow rate was maintained at 1 ml/min. Overlaine UV spectra of both the drugs showed that PCM, DMP and TMD absorbed appreciably at 278 nm, so detection was carried out at 278 nm (Figure 2).

Validation of the method

Linearity: Linearity of the method was evaluated by constructing calibration curves at five concentration levels over a range of 0.2–1 µg/ml of DMP, 6.5–32.5 µg/ml of PCM and 0.75–3.75 µg/ml of TMD respectively. The calibration curves were developed by plotting peak area versus concentration (n=6) (Figure 3).

Specificity: The specificity of the method was ascertained by

Validation of the method

Linearity: Linearity of the method was evaluated by constructing calibration curves at five concentration levels over a range of 0.2–1 µg/ml of DMP, 6.5–32.5 µg/ml of PCM and 0.75–3.75 µg/ml of TMD respectively. The calibration curves were developed by plotting peak area versus concentration (n=6) (Figure 3).

Specificity: The specificity of the method was ascertained by

| Sample                     | Correlation of center and slope spectra | r (s, m) | r (m, e) |
|----------------------------|----------------------------------------|----------|----------|
| PCM                        |                                        | 0.991    | 0.998    |
| PCM tablet formulation A   |                                        | 0.997    | 0.997    |
| PCM tablet formulation B   |                                        | 0.995    | 0.996    |
| DMP                        |                                        | 0.998    | 0.995    |
| DMP tablet formulation A   |                                        | 0.996    | 0.996    |
| DMP tablet formulation B   |                                        | 0.996    | 0.995    |
| TMD                        |                                        | 0.995    | 0.998    |
| TMD tablet formulation A   |                                        | 0.996    | 0.997    |
| TMD tablet formulation B   |                                        | 0.998    | 0.996    |

Table 1: Peak purity correlation results of PCM, DMP and TMD in two formulations at peak start, middle and end using PDA detector (WATERS HPLC, MODEL NO. 1752).
assured by comparing the chromatogram (Figure 4, Table 1) with those of standards. The peak purity of PCM, DMP and TMD was confirmed by comparing Rt values and respective spectra of sample for tablet formulations. The bands of PCM, DMP and TMD were polyethylene glycol, lactose and micro-crystalline cellulose were used analyzing PCM, DMP and TMD in presence of excipients like talc, Cation:

- Limit of detection
- Precision

The intra-day and inter-day precision studies were carried out by estimating the corresponding responses 3 times on the same day and on 3 different days for three different concentrations of DMP (0.2, 0.6, 1 µg/ml), PCM (6.5, 19.5, 32.5 µg/ml) and TMD (0.75, 2.25, 3.75 µg/ml), and the results were simultaneously compared with the freshly prepared PCM, DMP and TMD and the results were simultaneously compared with the following equation as per ICH guidelines (Table 3).

Robustness: Acceptable %RSD values obtained after making small deliberate changes in the developed HPTLC method indicate that the method is robust for the intended purpose (Table 4).

Solution stability: The solutions at analytical concentration DMP (1 µg/ml), PCM (32.5 µg/ml) and TMD (3.75 µg/ml) were prepared and stored at room temperature for 24 h and analyzed at interval of 0, 6, 12 and 24 h for the presence of any band other than that of PCM, DMP and TMD and the results were simultaneously compared with the freshly prepared PCM, DMP and TMD standard solution of the same concentration in the form of change in %RSD of the response obtained.

Table 4: Results from the robustness study of method.

| Parameter                      | Method condition | R<sub>2</sub> | % rSD of peak area | Table 3: Summary of validation parameters of developed HPLC method.
|--------------------------------|------------------|--------------|---------------------|----------------|
| Range                          | DOM              | 0.2-1 µg/ml  | 6.5-32.5 µg/ml      |
| Retention time (min)           | DOM              | 5.18         | 3.76                |
| Tailing factor                 | DOM              | 1.29         | 1.32                |
| Resolution                     | DOM              | 2.4          | 1.14                |
| Theoretical Plates             | DOM              | 9769         | 13000               |
| Detection limit (ng/ml)        | DOM              | 1.06         | 20                  |
| Quantitation limit (ng/ml)     | DOM              | 3.23         | 60                  |
| Accuracy (%)                   | DOM              | 99.4-100.4   | 99.40 - 100.3       |
| Precision (%RSD)               | DOM              | 98.4 - 101.9 | 98.4 - 101.9        |
| Intra-day (n=3)                | DOM              | 0.54-1.56    | 0.53 - 1.74         |
| Inter-day (n=3)                | DOM              | 0.54-1.69    | 0.65 - 1.88         |
| Instrument precision (%RSD)    | DOM              | 0.19-0.54    | 0.18 - 0.63         |
| Specificity                    | DOM              | Specific     | Specific             |

Table 2: Results from accuracy study.

| Parameters                      | DOM | TMD | TMD |
|---------------------------------|-----|-----|-----|
| Range                           | 0.2-1 µg/ml | 6.5-32.5 µg/ml | 0.75-3.75 µg/ml |
| Retention time (min)            | 5.18 | 3.76 | 4.28 |
| Tailing factor                  | 1.29 | 1.32 | 1.14 |
| Resolution                      | 2.4  | 1.14 | 1.14 |
| Theoretical Plates              | 9769 | 13000 | 14000 |
| Detection limit (ng/ml)         | 1.06 | 20  | 2   |
| Quantitation limit (ng/ml)      | 3.23 | 60  | 6   |
| Accuracy (%)                    | 99.4-100.4 | 99.40 - 100.3 | 98.4 - 101.9 |
| Precision (%RSD)                | 98.4 - 101.9 | 98.4 - 101.9 | 98.4 - 101.9 |
| Intra-day (n=3)                 | 0.54-1.56 | 0.53 - 1.74 | 0.57-1.40 |
| Inter-day (n=3)                 | 0.54-1.69 | 0.65 - 1.88 | 0.14-0.32 |
| Instrument precision (%RSD)     | 0.19-0.54 | 0.18 - 0.63 | 0.61-0.79 |
| Specificity                     | Specific | Specific | Specific |

Table 5: Results from analysis of paracetamol, domperidone and tramadol HCl in the combined tablet dosage form. µg/ml) PCM (6.5, 19.5, 32.5 µg/ml) and TMD (0.75, 2.25, 3.75 µg/ml) six times and results are reported in terms of relative standard deviation (Table 3).

- Limits of detection (LOD) and Limits of quantification (LOQ): The limit of detection (LOD) is defined as the lowest concentration of an analyte that can reliably be differentiated from background levels. Limit of quantification (LOQ) of an individual analytical procedure is the lowest amount of analyte that can be quantitatively determined with suitable precision and accuracy. LOD and LOQ were calculated using following equation as per ICH guidelines (Table 3).

Table 6: Validation parameters of developed HPLC method.

| Tablet Component | Label claim (mg) | Amount found | % of label claim (n=5) ± % RSD (n=5) |
|------------------|------------------|-------------|-------------------------------------|
| Brand A PCM      | 325              | 324.8       | 99.583 ± 0.29                       |
| DMP              | 10               | 10.03       | 100.1 ± 0.65                        |
| TMD              | 37.5             | 37.48       | 99.32 ± 0.42                        |
| Brand B PCM      | 325              | 325.01      | 100.17 ± 0.42                       |
| DMP              | 10               | 9.98        | 99.64 ± 0.16                        |
| TMD              | 37.5             | 37.45       | 99.63 ± 0.27                        |

n=number of determinations

Table 7: Validation parameters of developed HPLC method.

| Parameter | Method condition | R<sub>2</sub> | % rSD of peak area |
|-----------|------------------|--------------|---------------------|
| Flow rate | 0.9 ml/min       | 6.12         | 5.46                |
|           | 1.1 ml/min       | 4.18         | 3.68                |
| Mobile phase ratio acetone:buffer | 65/35 | 4.38         | 3.18                |
|           | 35/65            | 6.18         | 5.28                |

Analyzing PCM, DMP and TMD in presence of excipients like t alc, polyethylene glycol, lactose and micro-crystalline cellulose were used for tablet formulations. The bands of PCM, DMP and TMD were confirmed by comparing Rt values and respective spectra of sample with those of standards. The peak purity of PCM, DMP and TMD was assured by comparing the chromatogram (Figure 4, Table 1).

Accuracy: The accuracy of the method was determined by calculating recoveries of PCM, DMP and TMD by method of standard additions. Known amount of DMP (80%, 100%, 120%), PCM(80%, 100%, 120%) and TMD (80%, 100%, 120%) were added to a pre quantified sample solution, and the amount of PCM, DMP and TMD were estimated by measuring the peak areas and by fitting these values to the straight-line equation of calibration curve (Table 2).

Precision: The intra-day and inter-day precision studies were carried out by estimating the corresponding responses 3 times on the same day and on 3 different days for three different concentrations of DMP (0.2, 0.6, 1 µg/ml), PCM (6.5, 19.5, 32.5 µg/ml) and TMD (0.75, 2.25, 3.75 µg/ml), and the results are reported in terms of relative standard deviation. The instrumental precision studies were carried out by estimating response of 3 different concentrations of DMP (0.2, 0.6, 1
determination of PCM, DMP and TMD in its pharmaceutical capsule formulations. Moreover it has advantages of short run time and the possibility of analysis of a large number of samples, both of which significantly reduce the analysis time per sample. Hence this method can be conveniently used for routine quality control analysis of PCM, DMP and TMD in its pharmaceutical formulations.

Acknowledgment

The authors are thankful to Cadilla Pharmaceuticals Ltd., Ahmedabad for providing gift sample of paracetamol, domperidone and tramadol HCI. The authors are very thankful to Sophisticated Instrumentation Center for Applied Research & Testing (SICART), Vallabh Vidyanagar, India, for providing necessary facilities to carryout research work. The authors are also thank full to indukaka ipocwala college of pharmacy (ICP) for providing laboratories facilities.

References

1. Control of pain in patients with cancer sign. Guidelines 40 Section 6.
2. Lewis KS, Han NH (1997) Tramadol: A new centrally acting analgesic. Am J Health Syst Pharm 54: 643-652.
3. Toral MI, Rivas J, Marta S, Soto C, Sandra O (2008) Simultaneous determination of acetaminophen and tramadol by second derivative spectrophotometry. J Chin Chem Soc 53: 1543-1547.
4. Sinrivasan KK, Alex J, Shrinivasak AA, Jacob S, Sunil Kumar MR, et al. (2007) Simultaneous derivative spectrophotometric estimation of aceclofenac and tramadol with paracetamol in combination solid dosage forms. Ind J Pharm Sci 69: 540-545.
5. Akhmani A, Sarlak N, Zarei AR (2006) Spectrophotometric determination of salicylamide and paracetamol in biological samples and pharmaceutical formulations by a differential kinetic method. Acta Chim Slov 53: 357-362.
6. Ayse K, Yucei K (2005) Determination of tramadol hydrochloride in ampoule dosage forms by using UV spectrophotometric and HPLC-DAD methods in methanol and water media. II Farmaco 60: 163-169.
7. Momin MY, Yeole PG, Puranik MP, Yadav SK (2006) Reverse phase HPLC method for determination of aceclofenac and paracetamol in tablet dosage form. Ind J Pharm Sci 68: 387-389.
8. Gandhimathi M, Ravi TK, Nilima S, Sowmya G (2007) High performance thin layer chromatographic method for simultaneous estimation of paracetamol and valdecoxib in tablet dosage form. Ind J Pharm Sci 69: 145-147.
9. Gopinath R, Rajan S, Mysyanath SH, Krishnaveer N, Suresh B (2007) A RP-HPLC method for simultaneous estimation of paracetamol and aceclofenac in tablets. Ind J Pharm Sci 69: 137-140.
10. Kirthik A, Subramanian G, Ranjith Kumar A, Udupa N (2007) Simultaneous estimation of paracetamol and domperidone in tablets by reverse phase HPLC method. Ind J Pharm Sci 69: 142-144.
11. Levent AM (2002) HPLC method for the analysis of paracetamol, caffeine and diprynone. Turk J Chem 26: 521-528.
12. Wijin FK, Tini P, Gunawan I (2005) HPLC determination and validation of tramadol hydrochloride in capsules. J Liq Chromatogr Related Tech 27: 737-744.
13. Yaldia HA, Faezeh SH, About-Einey Y, Alireza F (2006) Development and validation of a rapid hplc method for simultaneous determination of tramadol and its two main metabolites in human plasma. J Chromatogr B Analys Technol Biomed Lif Sci 830: 207-211.
14. Li Q, Wang R (2006) Simultaneous analysis of tramadol, metoprolol and their metabolites in human plasma and urine by high performance liquid chromatography. Chin Med J 119: 2013-2021.
15. Staerk U, Kulpmann WR (2000) High-temperature solid-phase microextraction procedure for the detection of drugs by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 745: 399-411.
16. Gandhimathia M, Ravi TK (2008) Simultaneous densitometric analysis of tramadol hydrochloride and chlorzoxazone by high-performance thin-layer chromatography. Modern TLC 21: 305-307.
17. Venkateshwarlu K, Reddy YN, Srisailam K, Rajkumar V, Pai MG (2008) Determination of tramadol in capsules by high performance thin layer chromatography–densitometry. Current Trends Biotechn Pharm 2: 421-425.
18. Krzek J, Starek MG (2003) Quality assessment for tramadol in pharmaceutical preparations with thin layer chromatography and densitometry. J Sep Sci 26: 1359-1362.
19. Gandhip SV, Barhate NS, Patel BR, Panchal DD, Bothara KG (2008) A validated densitometric method for analysis of aceclofenac and paracetamol in bulk drugs and in combined tablet dosage forms. Acta Chromatogr 20: 175-182.
20. Zenita DO, Basavahai K, Vinay KB (2011) Spektrofotometrisko određivanje domperidona u farmaceutskim preparatima primenom reakcije oksidacije bromata. Chemical Industry and Chemical Engineering Quarterly 17: 81-89.
21. Kolhapali LP, Karape AK, Thomas AB, Nanda RK, Choudhari ME, et al. (2011) Simultaneous spectrophotometric estimation of paracetamol and desketoprofen trometamol in pharmaceutical dosage form. Der Pharma Chemica 3: 365-371.
22. Sathiyanaarayanan L, Kulkami P, Nikam AR, Mahadik KR (2011) Rapid densitometric method for simultaneous analysis of famotidine and domperidone in commercial formulations using HPTLC. Der Pharma Chemica 3: 134-143.
23. Atul P, Ashwini D, Shrikant F, Ratnakar A (2010) A validated reverse phase HPLC method for simultaneous determination of drotaverine hydrochloride and paracetamol in tablet dosage form. Int J Pharma Sci 2: 904-908.
24. Venkatesh P, Hepsy Kalarani D, Ravinda Reddy K (2010) Spectrophotometric method for the simultaneous estimation of paracetamol and domperidone in tablet dosage forms. Research J Pharmaceutical Bio And Chem Sci 1: 155-164.
25. Khatal LD, Kamble AV, Mahadik MV, Dhaneshwar SR (2010) Validated HPTLC method for simultaneous quantitation of paracetamol, diclofenac potassium, and famotidine in tablet formulation. J AOAC Int 93: 765-770.
26. Solomon Sam WD, Vijai Anand PR, Shukla R, Sivakumar R, Venkatnarayan R (2010) Application of TLC-densitometry method for simultaneous estimation of tramadol hcl and paracetamol in pharmaceutical dosage forms. Int J Chemtech Research 2: 1188-1193.
27. Kalra K, Naik S, Jarmal G, Mishra N (2009) Spectrophotometric method for the simultaneous estimation of paracetamol and domperidone in tablet formulation. Int J Adv Pharm Chem 5: 73-76.
28. Yadav A, Singh RM, Mathur SC, Saini PK, Singh GN (2009) A simple and sensitive HPTLC method for simultaneous analysis of domperidone and paracetamol in tablet dosage forms. J planar chromatogr 22:421-422.
29. Jain D, Kashve RN, Bhadun RN (2010) Simultaneous estimation of tramadol hydrochloride, paracetamol and domperidone by rp-hplc in tablet formulation. J Liq Chromatogr Relat Technol 33: 786-792.